Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.

Detalles Bibliográficos
Autores principales: Banerjee, Rahul, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604917/
https://www.ncbi.nlm.nih.gov/pubmed/33139895
http://dx.doi.org/10.1038/s41571-020-00448-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604917/
https://www.ncbi.nlm.nih.gov/pubmed/33139895
http://dx.doi.org/10.1038/s41571-020-00448-y

Ejemplares similares